Cargando…

A hypolipoprotein sepsis phenotype indicates reduced lipoprotein antioxidant capacity, increased endothelial dysfunction and organ failure, and worse clinical outcomes

OBJECTIVE: Approximately one-third of sepsis patients experience poor outcomes including chronic critical illness (CCI, intensive care unit (ICU) stay > 14 days) or early death (in-hospital death within 14 days). We sought to characterize lipoprotein predictive ability for poor outcomes and contr...

Descripción completa

Detalles Bibliográficos
Autores principales: Guirgis, Faheem W., Black, Lauren Page, Henson, Morgan, Labilloy, Guillaume, Smotherman, Carmen, Hopson, Charlotte, Tfirn, Ian, DeVos, Elizabeth L., Leeuwenburgh, Christiaan, Moldawer, Lyle, Datta, Susmita, Brusko, Todd M., Hester, Alexis, Bertrand, Andrew, Grijalva, Victor, Arango-Esterhay, Alexander, Moore, Frederick A., Reddy, Srinivasa T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447561/
https://www.ncbi.nlm.nih.gov/pubmed/34535154
http://dx.doi.org/10.1186/s13054-021-03757-5
_version_ 1784569041990451200
author Guirgis, Faheem W.
Black, Lauren Page
Henson, Morgan
Labilloy, Guillaume
Smotherman, Carmen
Hopson, Charlotte
Tfirn, Ian
DeVos, Elizabeth L.
Leeuwenburgh, Christiaan
Moldawer, Lyle
Datta, Susmita
Brusko, Todd M.
Hester, Alexis
Bertrand, Andrew
Grijalva, Victor
Arango-Esterhay, Alexander
Moore, Frederick A.
Reddy, Srinivasa T.
author_facet Guirgis, Faheem W.
Black, Lauren Page
Henson, Morgan
Labilloy, Guillaume
Smotherman, Carmen
Hopson, Charlotte
Tfirn, Ian
DeVos, Elizabeth L.
Leeuwenburgh, Christiaan
Moldawer, Lyle
Datta, Susmita
Brusko, Todd M.
Hester, Alexis
Bertrand, Andrew
Grijalva, Victor
Arango-Esterhay, Alexander
Moore, Frederick A.
Reddy, Srinivasa T.
author_sort Guirgis, Faheem W.
collection PubMed
description OBJECTIVE: Approximately one-third of sepsis patients experience poor outcomes including chronic critical illness (CCI, intensive care unit (ICU) stay > 14 days) or early death (in-hospital death within 14 days). We sought to characterize lipoprotein predictive ability for poor outcomes and contribution to sepsis heterogeneity. DESIGN: Prospective cohort study with independent replication cohort. SETTING: Emergency department and surgical ICU at two hospitals. PATIENTS: Sepsis patients presenting within 24 h. METHODS: Measures included cholesterol levels (total cholesterol, high density lipoprotein cholesterol [HDL-C], low density lipoprotein cholesterol [LDL-C]), triglycerides, paraoxonase-1 (PON-1), and apolipoprotein A-I (Apo A-I) in the first 24 h. Inflammatory and endothelial markers, and sequential organ failure assessment (SOFA) scores were also measured. LASSO selection assessed predictive ability for outcomes. Unsupervised clustering was used to investigate the contribution of lipid variation to sepsis heterogeneity. MEASUREMENTS AND MAIN RESULTS: 172 patients were enrolled. Most (~ 67%, 114/172) rapidly recovered, while ~ 23% (41/172) developed CCI, and ~ 10% (17/172) had early death. ApoA-I, LDL-C, mechanical ventilation, vasopressor use, and Charlson Comorbidity Score were significant predictors of CCI/early death in LASSO models. Unsupervised clustering yielded two discernible phenotypes. The Hypolipoprotein phenotype was characterized by lower lipoprotein levels, increased endothelial dysfunction (ICAM-1), higher SOFA scores, and worse clinical outcomes (45% rapid recovery, 40% CCI, 16% early death; 28-day mortality, 21%). The Normolipoprotein cluster patients had higher cholesterol levels, less endothelial dysfunction, lower SOFA scores and better outcomes (79% rapid recovery, 15% CCI, 6% early death; 28-day mortality, 15%). Phenotypes were validated in an independent replication cohort (N = 86) with greater sepsis severity, which similarly demonstrated lower HDL-C, ApoA-I, and higher ICAM-1 in the Hypolipoprotein cluster and worse outcomes (46% rapid recovery, 23% CCI, 31% early death; 28-day mortality, 42%). Normolipoprotein patients in the replication cohort had better outcomes (55% rapid recovery, 32% CCI, 13% early death; 28-day mortality, 28%) Top features for cluster discrimination were HDL-C, ApoA-I, total SOFA score, total cholesterol level, and ICAM-1. CONCLUSIONS: Lipoproteins predicted poor sepsis outcomes. A Hypolipoprotein sepsis phenotype was identified and characterized by lower lipoprotein levels, increased endothelial dysfunction (ICAM-1) and organ failure, and worse clinical outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-021-03757-5.
format Online
Article
Text
id pubmed-8447561
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84475612021-09-17 A hypolipoprotein sepsis phenotype indicates reduced lipoprotein antioxidant capacity, increased endothelial dysfunction and organ failure, and worse clinical outcomes Guirgis, Faheem W. Black, Lauren Page Henson, Morgan Labilloy, Guillaume Smotherman, Carmen Hopson, Charlotte Tfirn, Ian DeVos, Elizabeth L. Leeuwenburgh, Christiaan Moldawer, Lyle Datta, Susmita Brusko, Todd M. Hester, Alexis Bertrand, Andrew Grijalva, Victor Arango-Esterhay, Alexander Moore, Frederick A. Reddy, Srinivasa T. Crit Care Research OBJECTIVE: Approximately one-third of sepsis patients experience poor outcomes including chronic critical illness (CCI, intensive care unit (ICU) stay > 14 days) or early death (in-hospital death within 14 days). We sought to characterize lipoprotein predictive ability for poor outcomes and contribution to sepsis heterogeneity. DESIGN: Prospective cohort study with independent replication cohort. SETTING: Emergency department and surgical ICU at two hospitals. PATIENTS: Sepsis patients presenting within 24 h. METHODS: Measures included cholesterol levels (total cholesterol, high density lipoprotein cholesterol [HDL-C], low density lipoprotein cholesterol [LDL-C]), triglycerides, paraoxonase-1 (PON-1), and apolipoprotein A-I (Apo A-I) in the first 24 h. Inflammatory and endothelial markers, and sequential organ failure assessment (SOFA) scores were also measured. LASSO selection assessed predictive ability for outcomes. Unsupervised clustering was used to investigate the contribution of lipid variation to sepsis heterogeneity. MEASUREMENTS AND MAIN RESULTS: 172 patients were enrolled. Most (~ 67%, 114/172) rapidly recovered, while ~ 23% (41/172) developed CCI, and ~ 10% (17/172) had early death. ApoA-I, LDL-C, mechanical ventilation, vasopressor use, and Charlson Comorbidity Score were significant predictors of CCI/early death in LASSO models. Unsupervised clustering yielded two discernible phenotypes. The Hypolipoprotein phenotype was characterized by lower lipoprotein levels, increased endothelial dysfunction (ICAM-1), higher SOFA scores, and worse clinical outcomes (45% rapid recovery, 40% CCI, 16% early death; 28-day mortality, 21%). The Normolipoprotein cluster patients had higher cholesterol levels, less endothelial dysfunction, lower SOFA scores and better outcomes (79% rapid recovery, 15% CCI, 6% early death; 28-day mortality, 15%). Phenotypes were validated in an independent replication cohort (N = 86) with greater sepsis severity, which similarly demonstrated lower HDL-C, ApoA-I, and higher ICAM-1 in the Hypolipoprotein cluster and worse outcomes (46% rapid recovery, 23% CCI, 31% early death; 28-day mortality, 42%). Normolipoprotein patients in the replication cohort had better outcomes (55% rapid recovery, 32% CCI, 13% early death; 28-day mortality, 28%) Top features for cluster discrimination were HDL-C, ApoA-I, total SOFA score, total cholesterol level, and ICAM-1. CONCLUSIONS: Lipoproteins predicted poor sepsis outcomes. A Hypolipoprotein sepsis phenotype was identified and characterized by lower lipoprotein levels, increased endothelial dysfunction (ICAM-1) and organ failure, and worse clinical outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-021-03757-5. BioMed Central 2021-09-17 /pmc/articles/PMC8447561/ /pubmed/34535154 http://dx.doi.org/10.1186/s13054-021-03757-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Guirgis, Faheem W.
Black, Lauren Page
Henson, Morgan
Labilloy, Guillaume
Smotherman, Carmen
Hopson, Charlotte
Tfirn, Ian
DeVos, Elizabeth L.
Leeuwenburgh, Christiaan
Moldawer, Lyle
Datta, Susmita
Brusko, Todd M.
Hester, Alexis
Bertrand, Andrew
Grijalva, Victor
Arango-Esterhay, Alexander
Moore, Frederick A.
Reddy, Srinivasa T.
A hypolipoprotein sepsis phenotype indicates reduced lipoprotein antioxidant capacity, increased endothelial dysfunction and organ failure, and worse clinical outcomes
title A hypolipoprotein sepsis phenotype indicates reduced lipoprotein antioxidant capacity, increased endothelial dysfunction and organ failure, and worse clinical outcomes
title_full A hypolipoprotein sepsis phenotype indicates reduced lipoprotein antioxidant capacity, increased endothelial dysfunction and organ failure, and worse clinical outcomes
title_fullStr A hypolipoprotein sepsis phenotype indicates reduced lipoprotein antioxidant capacity, increased endothelial dysfunction and organ failure, and worse clinical outcomes
title_full_unstemmed A hypolipoprotein sepsis phenotype indicates reduced lipoprotein antioxidant capacity, increased endothelial dysfunction and organ failure, and worse clinical outcomes
title_short A hypolipoprotein sepsis phenotype indicates reduced lipoprotein antioxidant capacity, increased endothelial dysfunction and organ failure, and worse clinical outcomes
title_sort hypolipoprotein sepsis phenotype indicates reduced lipoprotein antioxidant capacity, increased endothelial dysfunction and organ failure, and worse clinical outcomes
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447561/
https://www.ncbi.nlm.nih.gov/pubmed/34535154
http://dx.doi.org/10.1186/s13054-021-03757-5
work_keys_str_mv AT guirgisfaheemw ahypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT blacklaurenpage ahypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT hensonmorgan ahypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT labilloyguillaume ahypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT smothermancarmen ahypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT hopsoncharlotte ahypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT tfirnian ahypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT devoselizabethl ahypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT leeuwenburghchristiaan ahypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT moldawerlyle ahypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT dattasusmita ahypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT bruskotoddm ahypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT hesteralexis ahypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT bertrandandrew ahypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT grijalvavictor ahypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT arangoesterhayalexander ahypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT moorefredericka ahypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT reddysrinivasat ahypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT guirgisfaheemw hypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT blacklaurenpage hypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT hensonmorgan hypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT labilloyguillaume hypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT smothermancarmen hypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT hopsoncharlotte hypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT tfirnian hypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT devoselizabethl hypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT leeuwenburghchristiaan hypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT moldawerlyle hypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT dattasusmita hypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT bruskotoddm hypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT hesteralexis hypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT bertrandandrew hypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT grijalvavictor hypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT arangoesterhayalexander hypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT moorefredericka hypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes
AT reddysrinivasat hypolipoproteinsepsisphenotypeindicatesreducedlipoproteinantioxidantcapacityincreasedendothelialdysfunctionandorganfailureandworseclinicaloutcomes